Oscient Pharma (OSCI) Reports Smaller Q4 Loss
More News related to OSCI
- Oscient Pharmaceuticals (OSCI) Files Chapter 11 Bankruptcy; Shares Deemed No Value
- Oscient Pharmaceuticals (OSCI) Discontinues Direct Selling of its Products; Eliminates 150-Person Sales Force
- Oscient Pharma (OSCI) Reports Smaller Q4 Loss
- Oscient Pharmaceuticals (OSCI) Cuts 32% of Workforce
- Oscient Pharmaceuticals (OSCI) Completes Convertible Exchange Offer; to Issue $85M in New 12.5% Convertible Senior Notes and 21M Shares of Common Stock
More News related to Earnings
- Radient Pharma (RPC) Posts Q3 Loss of $0.31, Wider Y/Y; Revs Lower
- Brocade (BRCD) Q4 Sales Jump, CEO Forced To Address Rumors
- Highlights From Brocade Communications's (BRCD) Q4 Q&A Session; Reaffirms FY10 Outlook
- Highlights From HPQ's Q4 Conference Call: Seeing Continued Turnaround, EDS Integration Going Well; Guides Higher for FY10
- H.J. Heinz (HNZ) Serves Up a Beat And Raise Quarter, But Shares Dip
Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) reports Q4 loss of $0.50, compared to a loss of $1.08 in the same quarter last year. Revenues for the quarter were $26.4 million, versus $25.3 million in Q407.
Related Categories
EarningsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
